We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allergan plc | NYSE:AGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
TIDM0QCV TIDM0Y7T FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1) State Street Global Advisors & Affiliates --------------------------------------------- ------------------------------- Company dealt in AbbVie Inc. --------------------------------------------- ------------------------------- Class of relevant security to which US$0.01 common stock the dealings being disclosed relate (Note 2) --------------------------------------------- ------------------------------- Date of dealing 26(th) March 2020 --------------------------------------------- ------------------------------- 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short ------------------------------------- -------------------- ----------- Number (%) Number (%) ------------------------------------- ---------- -------- ------ --- (1) Relevant securities 68,193,063 4.61802% ------------------------------------- ---------- -------- ------ --- (2) Derivatives (other than options) N/A ------------------------------------- ---------- -------- ------ --- (3) Options and agreements to purchase/sell N/A ------------------------------------- ---------- -------- ------ --- Total 68,193,063 4.61802% ------------------------------------- ---------- -------- ------ --- (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short ------------------------------------------- ----------- ----------- Number (%) Number (%) ------------------------------------------- ------ --- ------ --- (1) Relevant securities N/A ------------------------------------------- ------ --- ------ --- (2) Derivatives (other than options) N/A ------------------------------------------- ------ --- ------ --- (3) Options and agreements to purchase/sell N/A ------------------------------------------- ------ --- ------ --- Total N/A ------------------------------------------- ------ --- ------ --- 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 5) -------------- ----------------------------- ----------------------- Purchase 300 73.84 -------------- ----------------------------- ----------------------- Purchase 57,400 72.02 -------------- ----------------------------- ----------------------- Purchase 681 73.83 -------------- ----------------------------- ----------------------- Purchase 1,449 73.83 -------------- ----------------------------- ----------------------- Purchase 32,641 73.83 -------------- ----------------------------- ----------------------- Purchase 7,300 73.83 -------------- ----------------------------- ----------------------- Purchase 83,900 73.83 -------------- ----------------------------- ----------------------- Purchase 1,400 73.83 -------------- ----------------------------- ----------------------- Purchase 879 73.83 -------------- ----------------------------- ----------------------- Purchase 586 73.83 -------------- ----------------------------- ----------------------- Purchase 4,292 73.83 -------------- ----------------------------- ----------------------- Purchase 1,056 73.83 -------------- ----------------------------- ----------------------- Purchase 4,032 73.83 -------------- ----------------------------- ----------------------- Purchase 24,492 73.83 -------------- ----------------------------- ----------------------- Purchase 801 73.83 -------------- ----------------------------- ----------------------- Purchase 569 73.83 -------------- ----------------------------- ----------------------- Sale 300 73.83 -------------- ----------------------------- ----------------------- Sale 1,999 73.83 -------------- ----------------------------- ----------------------- Sale 200 73.83 -------------- ----------------------------- ----------------------- Sale 26 72.10 -------------- ----------------------------- ----------------------- Sale 8,890 73.83 -------------- ----------------------------- ----------------------- Sale 62,230 73.83 -------------- ----------------------------- ----------------------- Sale 27,804 73.83 -------------- ----------------------------- ----------------------- Sale 300 73.83 -------------- ----------------------------- ----------------------- Sale 1,040 73.83 -------------- ----------------------------- ----------------------- Sale 495 73.83 -------------- ----------------------------- ----------------------- Sale 4,400 73.83 -------------- ----------------------------- ----------------------- Sale 1,938 73.83 -------------- ----------------------------- ----------------------- Sale 969 73.83 -------------- ----------------------------- ----------------------- Sale 1,800 73.83 -------------- ----------------------------- ----------------------- Sale 306 66.47 -------------- ----------------------------- ----------------------- (b) Derivatives transactions (other than options transactions) Product name, Nature of transaction Number of relevant securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) ------------- --------------------- ----------------------------- -------------- N/A ------------- --------------------- ----------------------------- -------------- (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money e.g. call option purchasing securities to which price American, date paid/received varying etc. the option relates European etc. per unit (Note 5) (Note 7) ----------------- ----------------- -------------------- -------- -------------- ------ ------------------ N/A ----------------- ----------------- -------------------- -------- -------------- ------ ------------------ (ii) Exercising Product name, Number of securities Exercise price per e.g. call option unit (Note 5) ----------------- -------------------- ------------------ N/A ----------------- -------------------- ------------------ (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction Details Price per unit (Note 8) (if applicable) (Note 5) --------------------- ------- ------------------------- N/A --------------------- ------- ------------------------- 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. ----------------------------------------------------------- N/A ----------------------------------------------------------- Is a Supplemental Form 8 attached? (Note 9) NO ------------------------------------------------------- -----------------
Date of disclosure 27(th) March 2020 ------------------------------------------------------- ----------------- Contact name Lionel Colaco ------------------------------------------------------- ----------------- Telephone number 020 33956098 ------------------------------------------------------- ----------------- If a connected EFM, name of offeree/offeror with which N/A connected ------------------------------------------------------- ----------------- If a connected EFM, state nature of connection (Note N/A 10) ------------------------------------------------------- -----------------
(END) Dow Jones Newswires
March 27, 2020 10:29 ET (14:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions